Pfizer Prevenar 13 gets EMA recommendation for extension of indication

The Committee for Medicinal Products for Human Use, CHMP, adopted a positive opinion recommending a variation to the terms of the marketing authorization for the medicinal product Prevenar 13, held by Pfizer. The CHMP adopted a change to an indication as follows: ¡°Active immunisation for the prevention of invasive disease caused by Streptococcus pneumoniae in adults ¡Ý18 years of age and the elderly.¡±

View Comments (0)